Nu Skin Enterprises (NUS) Cash & Equivalents (2009 - 2026)

Nu Skin Enterprises (NUS) has 18 years of Cash & Equivalents data on file, last reported at $198.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 2.51% year-over-year to $198.7 million; the trailing twelve-month figure through Mar 2026 stood at $198.7 million (down 2.51% YoY), and the FY2025 full-year result was $238.6 million, up 27.69% from the prior year.
• Cash & Equivalents declined to $198.7 million in Q1 2026, from $238.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $363.9 million in Q2 2022 to a low of $186.9 million in Q4 2024.
• A 5-year average of $246.4 million and a median of $235.6 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 35.27% in 2023 and rose 27.69% in 2025, its largest moves.
• Tracing NUS's Cash & Equivalents over 5 years: stood at $264.7 million in 2022, then retreated by 3.27% to $256.1 million in 2023, then slipped by 27.02% to $186.9 million in 2024, then climbed by 27.69% to $238.6 million in 2025, then dropped by 16.75% to $198.7 million in 2026.
• Business Quant data shows NUS's Cash & Equivalents at $198.7 million in Q1 2026, $238.6 million in Q4 2025, and $251.8 million in Q3 2025.